The much anticipated KDIGO CKD-MBD Guidelines have recently been published (Full CKD-MBD Guidelines), along with an Executive Summary and summaries of the Evidence used in the update. The new guidelines are the result of significant effort by the KDIGO Guidelines Work Group and Evidence Review Team following the 2013 Controversies…
Patients with both chronic kidney disease and heart failure present a unique range of challenges to physicians, particularly in relation to the use of Renin Angiotensin Aldosteron System Inhibition (RAASi). Cardio-renal patients are treated with RAASi therapy at high doses[1] due to their positive effects in reducing proteinuria, hypertension and…
The KDIGO 2017 CKD-MBD Guidelines have now been officially released and are available online: 2017 KDIGO CKD-MBD Guidelines The new guidelines were developed following a Controversies Conference in 2013 that identified several areas within the 2009 Guidelines which warranted potential revision or deletion, along with a series of topics to…
Balancing the cardio-renal benefits of RAASi therapy against the risks of hyperkalaemia in CKD patients is a significant challenge. ERA-EDTA 2017 provided an update on this topic, along with the status of novel potassium (K+) binders and their role in maintaining RAASi use. This article gives an overview of the…
The CKD-MBD track at the recent ERA-EDTA 2017 Congress featured numerous sessions, focusing on a broad range of topics. In this congress review article we focus on presentations regarding phosphate binders and active vitamin D therapy. Phosphate binders: Factors influencing prescription choice The much-anticipated 2017 KDIGO guidelines update continues to…
The benefits and risks of IV iron therapy were again a topic of discussion at the recent ERA-EDTA 2017 congress, with data on IV iron’s positive effects in heart failure patients also highlighted. This summary provides an overview of the relevant sessions from the congress. The benefits and risks of…
Iron deficiency anaemia (IDA) is an acknowledged co-morbidity of chronic kidney disease (CKD),(1,2) and the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical guidelines provide recommendations on its diagnosis and treatment as part of the management of anaemia in patients with CKD.(3) Iron therapy has become one of the mainstay…
ERA-EDTA 2017 is fast approaching and, to help you plan your time at the Congress, the COMPACT RENAL team has put together a preview guide to the presentations relating to iron deficiency and anaemia. For full listings for the conference see the ERA-EDTA Planner. COMPACT RENAL will be in the…
ERA-EDTA 2017 is fast approaching and, to help you plan your time at the Congress, the COMPACT RENAL team has put together a preview guide to the presentations in the field of CKD-MBD. For full listings for the conference see the ERA-EDTA Planner. COMPACT RENAL will be in the exhibit…
ERA-EDTA 2017 is fast approaching and, to help you plan your time at the Congress, the COMPACT RENAL team has put together a preview guide to the posters and presentations relating to hyperkalaemia. For full listings for the conference see the ERA-EDTA Planner. COMPACT RENAL will be in the exhibit…
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the management of CKD-MBD are due to be updated in Q2 2017.[1] Literature review is a key component of any guidelines update and the KDIGO committee has highlighted in advance new studies which they believe to be relevant to the treatment…
Vitamin D is an integral and vital part of the complex management of calcium, phosphate and parathyroid hormone homeostasis.[1] In patients with chronic kidney disease (CKD) vitamin D insufficiency (25 hydroxyvitamin D (25(OH)D) < 30ng/mL) is extremely common and is estimated to affect 71–83% of patients with stage 3 or…
